Jardiance and Metformin Interaction Explained

Jardiance is the brand name for empagliflozin, an SGLT2 (sodium-glucose cotransporter-2) inhibitor. Metformin is a biguanide. Both are oral medications for type 2 diabetes, and both are also FDA-approved individually for uses beyond glycemic control (empagliflozin for heart failure and chronic kidney disease). They are frequently prescribed together and are sold as a fixed-dose combination tablet, Synjardy.

Direct answer: Empagliflozin and metformin do not share a metabolic pathway and there is no established pharmacokinetic drug-drug interaction between them, a conclusion reflected in the Synjardy prescribing information. The interaction that actually matters is pharmacodynamic and indirect: both drugs depend on adequate kidney function, and as eGFR declines, metformin's risk of accumulation and lactic acidosis rises at roughly the same range where empagliflozin's glucose-lowering effect (though not necessarily its cardiorenal benefit) weakens. This is a monitoring problem, not a metabolic clash, and it requires tracking one shared lab value, not adjusting either drug's dose against the other.

What is established, what is plausible, and what is not

Established: No meaningful pharmacokinetic interaction. Empagliflozin is cleared largely through glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9) and does not meaningfully affect CYP3A4, CYP2C8, or P-glycoprotein. Metformin is not hepatically metabolized and is eliminated unchanged by the kidney via OCT2 and MATE transporters. These pathways do not overlap, and the FDA-approved Synjardy label does not carry a dose-adjustment warning for co-administration.

Established: Metformin's lactic acidosis risk rises with declining renal function, and the FDA revised its metformin labeling in 2016 to use eGFR-based thresholds rather than a fixed creatinine cutoff. A Cochrane systematic review found no increased risk of lactic acidosis or elevated lactate levels with metformin compared with other antihyperglycemic agents in trials that generally excluded patients with significant renal impairment, and the reviewers noted that reliable data at the population level to quantify absolute risk precisely were limited (Salpeter et al., Cochrane Database Syst Rev, 2010). Precise incidence figures and case-fatality percentages you may see quoted elsewhere should be checked against a current primary source before being used in patient counseling; this article does not cite a specific rate.

Established: Empagliflozin has demonstrated cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease, and heart failure benefit independent of diabetes status, in large randomized outcome trials (EMPA-REG OUTCOME and EMPEROR-Reduced), and kidney-outcome benefit in a broad chronic kidney disease population (EMPA-KIDNEY). These are well-documented headline trial results:

• EMPA-REG OUTCOME (N=7,020, type 2 diabetes with established cardiovascular disease) found a statistically significant reduction in the composite of cardiovascular death, nonfatal MI, and nonfatal stroke, and a reduction in heart failure hospitalization, with empagliflozin versus placebo added to standard care (Zinman et al., NEJM, 2015).
• EMPEROR-Reduced (N=3,730, heart failure with reduced ejection fraction) found empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization regardless of diabetes status (Packer et al., NEJM, 2020).
• EMPA-KIDNEY (N=6,609, broad chronic kidney disease population) found empagliflozin reduced progression of kidney disease or cardiovascular death versus placebo (EMPA-KIDNEY Collaborative Group, NEJM, 2023).

Secondary numeric detail from these trials, exact HbA1c deltas, exact percentage risk reductions to the decimal, exact baseline eGFR, weight change, or blood pressure change, is directionally consistent with what is widely reported about this drug class, but exact figures should be checked against the trial publication or a current label before being used in a clinical document, since this review could not independently re-verify every number against the primary paper.

Plausible but not established as a population-level effect: That empagliflozin's osmotic diuresis meaningfully raises metformin exposure by reducing renal perfusion during ordinary, non-acute use. This is a mechanistically reasonable concern (both drugs are renal-function dependent, and volume depletion reduces GFR), but it is not the same as a demonstrated pharmacokinetic interaction, and no data provided in the source material quantify this effect. The practical implication, sick-day dose holding and renal monitoring, does not depend on resolving this question.

Not established from the material reviewed here: A specific overlap of metformin with topiramate or zonisamide worsening lactic acidosis risk, and specific numeric HbA1c or weight results from a named add-on trial of empagliflozin to a metformin background. Both of these appear in earlier drafts of this topic but rely on citations that could not be matched with confidence to the exact claim, and are described below only in general, unquantified terms pending verification.

The two eGFR thresholds that matter, and why they don't align

The clinically important fact about this combination is that empagliflozin and metformin reach their respective safety and efficacy limits at slightly different points on the same downward eGFR curve, and clinicians should not assume that stopping or continuing one drug settles the question for the other.

• Metformin: per the FDA's 2016 label revision, do not initiate when eGFR is below 45 mL/min/1.73 m², and discontinue when eGFR falls below 30 mL/min/1.73 m².
• Empagliflozin: its glucose-lowering effect diminishes as filtered glucose load falls with declining eGFR, so it is not expected to meaningfully improve glycemic control once eGFR is quite low. However, current diabetes-care guidance from the American Diabetes Association generally supports continuing an SGLT2 inhibitor with demonstrated cardiovascular or kidney benefit even as eGFR declines toward the lower ranges studied in EMPA-KIDNEY, specifically for its organ-protective effect rather than its glucose-lowering effect (ADA Standards of Care, 2024). Readers should confirm the exact current eGFR floor in the ADA Standards for the year they are consulting, since guideline thresholds are periodically revised.

The practical failure mode this creates: a patient's eGFR drifts down over months. A clinician who is watching for "should I stop the SGLT2 inhibitor" may reasonably decide to continue it for cardiorenal protection, and then fail to separately ask "should metformin be stopped now," because the two decisions feel like one decision. They are not. Metformin's stop point is a hard, numeric, FDA-labeled threshold. Empagliflozin's continuation is a judgment call weighed against its non-glycemic benefit.

Evidence-status assessment: what to verify before relying on this combination

Monitoring that follows from the two thresholds

Regardless of exactly which eGFR cutoffs a given year's guideline uses, the operational monitoring pattern is the same:

1. Before starting either drug: check serum creatinine and eGFR, urine albumin-to-creatinine ratio, and liver function (hepatic impairment independently raises lactic acidosis risk with metformin because lactate clearance depends partly on the liver).
2. Periodically thereafter: check eGFR more frequently as it approaches the metformin thresholds above, roughly moving from annual checks in normal renal function to checks every few months as eGFR falls toward the 30 to 45 mL/min/1.73 m² range. Exact intervals should follow the current ADA or KDIGO guideline rather than a fixed schedule from this article.
3. At the metformin threshold: stop metformin per the FDA label. Separately and explicitly re-decide, do not default, whether empagliflozin should continue for a non-glycemic indication.
4. Around iodinated contrast: the FDA advises holding metformin around the time of iodinated contrast administration in patients with eGFR below 60 mL/min/1.73 m², hepatic impairment, or hemodynamic instability, and reassessing renal function before resuming. Empagliflozin does not carry the same contrast-hold instruction in its label, but any contrast-associated kidney injury should trigger reassessment of both drugs.
5. Sick days: illness with vomiting, diarrhea, fever, or reduced oral intake raises the risk of volume depletion and reduced renal perfusion. Standard sick-day guidance is to hold both metformin and empagliflozin until oral intake and hydration are back to normal, then resume once stable. This is a general principle reflected across diabetes-care guidance; individual instructions should come from the prescribing clinician.

Symptoms that warrant urgent evaluation

Patients on this combination, or on either drug alone, should seek urgent medical care for:

• Unexplained muscle pain, unusual fatigue, difficulty breathing, abdominal pain, or feeling unusually cold, these can be signs of lactic acidosis, a rare but serious complication of metformin accumulation.
• Signs of significant dehydration or low blood pressure (lightheadedness, fainting, markedly decreased urination), which can occur with empagliflozin's diuretic effect, especially during illness.
• Signs of diabetic ketoacidosis with relatively normal blood glucose (nausea, vomiting, abdominal pain, unusual tiredness), a recognized though uncommon risk with SGLT2 inhibitors that can occur even when glucose is not markedly elevated.

What this combination does not change

Neither drug meaningfully raises hypoglycemia risk on its own, since neither stimulates insulin secretion; hypoglycemia becomes a relevant concern mainly if a sulfonylurea or insulin is added to the regimen, at which point the added agent's dose typically needs review. The two drugs' glucose-lowering mechanisms (reduced hepatic glucose output for metformin, increased urinary glucose excretion for empagliflozin) do not overlap, so there is no pharmacodynamic antagonism between them, only the shared renal dependency described above.

Fixed-dose combination: Synjardy

Synjardy combines empagliflozin and metformin hydrochloride in a single tablet, in strengths of 5 mg/500 mg, 5 mg/1,000 mg, 12.5 mg/500 mg, and 12.5 mg/1,000 mg empagliflozin/metformin. An extended-release version, Synjardy XR, is available for patients who have gastrointestinal intolerance to immediate-release metformin. The FDA-approved Synjardy label does not include a dose-adjustment requirement for the combination beyond the renal-function considerations that apply to each component individually. Patients titrating toward the 10 mg empagliflozin dose used in cardiorenal indications, rather than a 5 mg dose intended mainly for glycemic add-on, may be better served initially by separate tablets until the target dose is confirmed.

References

1. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010. https://pubmed.ncbi.nlm.nih.gov/20393934/
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. https://www.nejm.org/doi/10.1056/NEJMoa1504720
3. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https://www.nejm.org/doi/10.1056/NEJMoa2022190
4. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. https://www.nejm.org/doi/10.1056/NEJMoa2204233
5. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1). https://diabetesjournals.org/care/issue/47/Supplement_1